Top

Documenta Ophthalmologica

Published in:

Open Access 01-04-2016 | Original Research Article

The macular function and structure in patients with diabetic macular edema before and after ranibizumab treatment

Authors: Barbara Nowacka, Marta Kirkiewicz, Katarzyna Mozolewska-Piotrowska, Wojciech Lubiński

Published in: Documenta Ophthalmologica | Issue 2/2016

Abstract

Purpose

To evaluate macular function and structure in patients with diabetic macular edema prior to, as well as 3 and 6 months after intravitreal ranibizumab treatment.

Patients and methods

Seventeen eyes of 17 patients with type 2 diabetes mellitus and diabetic macular edema (DME) were treated with intravitreal injections of 0.5 mg ranibizumab. Prior to the first injection, as well as after 3 and 6 months, the following examinations were performed: assessment of distance best-corrected visual acuity (log MAR), perception of metamorphopsia (M-Chart), slit lamp examination of the anterior and posterior segment of the eye (Volk 90D lens), evaluation of the retinal and choroidal circulation (fluorescein angiography), assessment of the structure and thickness of the macula (OCT), as well as evaluation of the macular function (PERG and mfERG).

Results

We observed that ranibizumab significantly improved visual acuity after 3 and 6 months from the beginning of the treatment, which was a consequence of reduced macular edema and vascular leakage. There was a statistically significant decrease in metamorphopsia frequency at month 3; however, at month 6 it was a statistically insignificant when compared to the baseline. The results of electrophysiological examinations revealed no improvement in ranibizumab-treated patients.

Conclusion

Improvement of visual acuity and reduction in macular thickness were maintained up to the 6-month follow-up. The results of electrophysiological examinations revealed that ranibizumab injections tend to stabilize bioelectrical macular function of the outer, middle and inner retinal layers, which was impossible to recognize on the basis of visual acuity and OCT. Therefore, the electrophysiological examinations should be used as an additional objective tool for the evaluation of the anti-VEGF treatment effectiveness in DME.

Nicholson BP, Schachat AP (2010) A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 248:915–930CrossRefPubMed

Klein R, Klein BE, Moss SE (1984) Visual impairment in diabetes. Ophthalmology 91:1–9CrossRefPubMed

Soheilian M, Garfami KH, Ramezani A, Yaseri M, Peyman GA (2012) Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina 32:314–321CrossRefPubMed

Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 91:1464–1474CrossRefPubMed

Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103:1796–1806CrossRef

Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP (2001) VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42:2408–2413PubMed

Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S (2002) Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 133:70–77CrossRefPubMed

Holm K, Schroeder M, Lövestam Adrian M (2015) Peripheral retinal function assessed with 30-Hz flicker seems to improve after treatment with Lucentis in patients with diabetic macular oedema. Doc Ophthalmol 131:43–51CrossRefPubMed

Comyn O, Sivaprasad S, Peto T, Neveu MM, Holder GE, Xing W, Bunce CV, Patel PJ, Egan CA, Bainbridge JW, Hykin PG (2014) A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). Am J Ophthalmol 157:960–970CrossRefPubMed

10.

Bach M, Brigell MG, Hawlina M, Holder GE, Johnson MA, McCulloch DL, Meigen T, Viswanathan S (2013) ISCEV standard for clinical pattern electroretinography (PERG): 2012 update. Doc Ophthalmol 126:1–7CrossRefPubMed

11.

Hood DC, Bach M, Brigell M, Keating D, Kondo M, Lyons JS, Marmor MF, McCulloch DL, Palmowski-Wolfe AM (2012) International society For clinical electrophysiology of vision. ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition). Doc Ophthalmol 124:1–13CrossRefPubMedPubMedCentral

12.

Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM (2006) A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113:1706–1712CrossRefPubMed

13.

Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33:2399–2405CrossRefPubMedPubMedCentral

14.

Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, Abraham P, Campochiaro PA (2009) READ-2 Study Group. Primary end point (6 months) results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology 116:2175–2181CrossRefPubMed

15.

Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS (2012) RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:789–801CrossRefPubMed

Title: The macular function and structure in patients with diabetic macular edema before and after ranibizumab treatment
Authors: Barbara Nowacka
Marta Kirkiewicz
Katarzyna Mozolewska-Piotrowska
Wojciech Lubiński
Publication date: 01-04-2016
Publisher: Springer Berlin Heidelberg
Published in: Documenta Ophthalmologica / Issue 2/2016
Print ISSN: 0012-4486
Electronic ISSN: 1573-2622
DOI: https://doi.org/10.1007/s10633-016-9531-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The macular function and structure in patients with diabetic macular edema before and after ranibizumab treatment

Abstract

Purpose

Patients and methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2016

The effect of nutritional supplementation on the multifocal electroretinogram in healthy eyes

Treatment of vitamin A deficiency retinopathy with sublingual vitamin A palmitate

Differentiation of murine models of “negative ERG” by single and repetitive light stimuli

Full-field electroretinogram in autism spectrum disorder

Maculopathy following exposure to visible and infrared radiation from a laser pointer: a clinical case study